BeiGene’s $2.08 Billion Registered Direct Offering

Goodwin Procter LLP advised BeiGene Ltd on the deal.

BeiGene Ltd. closed the pricing of a registered direct offering of 145,838,979 at a purchase price of $14.2308 per share (equivalent to a price of $185 per American Depositary Share), resulting in gross proceeds of approximately $2.08 billion and net proceeds, after estimated offering expenses, of $2.07 billion.

The offering was made without an underwriter or a placement agent and as a result BeiGene will not be paying any underwriting discounts in connection with this offering.

BeiGene intends to use the net proceeds from the offering for working capital and other general corporate purposes, as disclosed in further detail in the prospectus supplement to be filed in connection with the offering.

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,100+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer.

The Goodwin team advising BeiGene was led by Mitchell Bloom (Picture), Edwin O’Connor, Marishka DeToy, Humza Bokhari, Josh Dell, Kathryn Weston, James Matarese, Daniel Karelitz and Benjamin Gossels.

Involved fees earner: Mitchell Bloom – Goodwin Procter; Humza Bokhari – Goodwin Procter; Josh Dell – Goodwin Procter; Marishka DeToy – Goodwin Procter; Benjamin Gossels – Goodwin Procter; Daniel Karelitz – Goodwin Procter; James Matarese – Goodwin Procter; Edwin O’Connor – Goodwin Procter; Kathryn Weston – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: BeiGene, Ltd.;

Author: Ambrogio Visconti